Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core

加速药物合作——自身免疫和免疫疾病组织研究核心

• 批准号: 10687729
• 负责人: Joel Marvin Guthridge
• 金额: $ 14.13万
• 依托单位: OKLAHOMA MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-23 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10687729
• 关键词: Attention; Autoimmune; Autoimmune Diseases; Awareness; Biological Markers; Biopsy; Biotechnology; Caring; Cells; Certification; Characteristics; Cladribine; Clinical; Collection; Country; Data; Data Set; Database Management Systems; Dedications; Disease; Emerging Technologies; Ensure; Equipment and supply inventories; Foundations; Freezing; Government; Histology; Image; Immune; Immune System Diseases; Industry Standard; Information Systems; Infrastructure; Institution; Institutional Review Boards; International; Investments; Knowledge; Leadership; Location; Logistics; Lupus; Lupus Erythematosus; Manuals; Measurement; Mediating; Medical Research; Medicine; Methods; Mission; Modality; Molecular; Molecular Genetics; Molecular Profiling; Monitor; Multiomic Data; Oklahoma; Pathology; Patients; Phenotype; Play; Positioning Attribute; Procedures; Process; Protocols documentation; Psoriasis; Quality Control; Recording of previous events; Research; Rheumatoid Arthritis; Sampling; Science; Secure; Services; Shipping; Ships; Site; Sjogren' s Syndrome; Solid; Staff Development; Standardization; Support System; System; Systemic Lupus Erythematosus; Systems Integration; Technology; Testing; Tissue Banks; Tissue Sample; Tissue imaging; Tissues; Training; Universities; Work; adjudication; biobank; clinical application; clinically actionable; cohort; cost effective; design; digital imaging; digital pathology; distributed data; experience; high dimensionality; innovation; interest; migration; molecular phenotype; multiple omics; pathology imaging; phenotypic biomarker; programs; repository; single cell analysis; social; success; transcriptomics

Project Summary The successful Accelerating Medicines Partnership in RA/Lupus (AMP1) program focused on deconstructing disease tissues through single-cell transcriptomic technologies. AMP in Autoimmune and Immune-Mediated Diseases (AMP AIM) is poised to expand the understanding of the cellular components and interactions at play in four autoimmune disease target tissues with new spatially-oriented modalities of single-cell analyses. As in the AMP1, the AMP AIM will require high-quality samples for interrogation, standardized methods to assess sample quality and common molecular/phenotypic biomarker testing across all subjects for a clinically and molecularly well-phenotyped cohort to apply new cutting-edge technologies to re-construct disease. The OMRF tissue research core (TRC) is uniquely positioned to successfully deploy a centralized TRC across all Disease Teams for Lupus (SLE), RA, Sjogren’s Disease (SjD), and Psoriatic Spectrum Diseases (PSD). With a robust, existing infrastructure, capabilities, and leadership, the OMRF TRC will provide the Network with: 1) standardized protocols and manuals to be used across all parts of the Network, 2) centralized logistics for collection, transport, storage and dissemination, 3) centralized, trans-disease QC and initial testing of all samples in a continuous manner as samples are collected for early quality management and identification of samples of high importance, 4) tissue imaging (basic histology & initial high-dimensional) utilizing sample sparing workflows that provide scoring and QC of tissue, plus initial multi-omic, spatially-informed data sets, and 5) industry standard repository and image database systems. The OMRF TRC is centrally located, making it an ideal location for logistics management and, since it was the repository for AMP1 carries Network knowledge along with the extensive experience as repository for multiple other national consortiums, provides for continuity during transition to AMP AIM. The OMRF TRC already has infrastructure in place and the reputation that follows from strong leadership to continue to act as an ideal honest broker for the Network. The OMRF TRC has state-of-the-art facilities that are integrated with advanced technologies within its associated cores to receive, store, collect meaningful QC and initial data sets, and disseminate selected samples to technology and analytic cores (TAC) poised to provide data from emerging technologies to build upon the deep clinical and initial characterization data, to make extremely high- dimensional, robust datasets. Considering the longstanding history of the OMRF TRC in biobanking samples for autoimmune disease studies, the OMRF TRC is poised to a produce a solid foundation of banked samples, organized logistics, and initial multi-omic datasets that will setup the Network for success in reconstructing our mechanistic understanding and clinical application of these new data to better treat these autoimmune diseases.

项目摘要 成功的加速类风湿性关节炎/狼疮药物伙伴关系(AMP1)计划专注于解构 通过单细胞转录组技术获得疾病组织。AMP在自身免疫和免疫介导中的作用 疾病(AMP AIM)准备扩大对细胞组件和相互作用的理解 在四种自身免疫性疾病的靶组织中，采用了新的面向空间的单细胞分析模式。如中所示 AMP1，AMP AIM将需要高质量的样本进行讯问，标准化的方法进行评估 所有受试者的样本质量和共同的分子/表型生物标志物测试 分子表型良好的队列，应用新的尖端技术来重建疾病。 OMRF组织研究核心(TRC)具有成功部署集中式TRC的独特优势 所有针对狼疮(SLE)、类风湿性关节炎(RA)、干燥病(SJD)和银屑病谱系疾病的疾病小组 (PSD)。凭借强大的现有基础设施、能力和领导力，OMRF TRC将提供 网络：1)标准化协议和手册，可在网络的所有部分使用；2)集中化 收集、运输、储存和分发的物流，3)集中、跨疾病的质量控制和初始测试 在所有样品中以连续的方式收集样品，以便进行早期质量管理和鉴定 高重要性样本，4)利用样本进行组织成像(基础组织学和初始高维) 提供组织评分和质量控制的备用工作流，以及初始多组体、空间信息丰富的数据集， 以及5)行业标准的存储库和图像数据库系统。 OMRF TRC位于中心位置，使其成为后勤管理的理想地点，而且由于它是 AMP1的存储库包含网络知识以及作为存储库的丰富经验 多个其他国家联合体，为向AMP AIM过渡提供了连续性。OMRF TRC 已经建立了基础设施，并拥有强大的领导层带来的声誉，可以继续充当 网络公司理想的诚实经纪人。OMRF TRC拥有最先进的设施，与 相关核心内的先进技术，用于接收、存储、收集有意义的QC和初始数据集， 并将选定的样本分发给准备提供数据的技术和分析核心(TAC) 新兴技术，以深入的临床和初步特征数据为基础，使极高- 维度、健壮的数据集。 考虑到OMRF TRC在自身免疫性疾病生物库样本中的悠久历史 通过研究，OMRF TRC准备为库存样品、有组织的物流和 最初的多组数据集，将为成功重建我们的机制建立网络 了解和临床应用这些新数据，以更好地治疗这些自身免疫性疾病。